Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours Β· Estimated delivery Aug 22 - Aug 27
Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
Type 2 diabetes opens the best insurance and savings card pathways for diabetes-indicated drugs
It's expected to be FDA approved in 2026
Youre experiencing health complications that get worse with time (uncontrolled blood sugar, worsening knee pain, sleep apnea) You respond well to semaglutide or tirzepatide many people achieve 15-22% weight loss, which is life-changing You want a drug with a known long-term safety profile and years of real-world data You dont want to wait for something that may be delayed Watching and waiting might make sense if: Youve tried semaglutide and tirzepatide without adequate results retatrutides triple mechanism may work where dual or single agonists didnt Youve plateaued on a current GLP-1/GIP medication and need more weight loss You have significant fatty liver disease retatrutides liver fat data is dramatically superior to anything available Youre comfortable enrolling in a clinical trial Your doctor recommends a watchful approach based on your specific situation What you should NOT do Dont wait indefinitely if you have a medical need now
